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Introduction 
 
Boron neutron capture therapy (BNCT) is a binary treatment 
modality, based on the high cross section of 10B to capture 
thermal neutrons producing two densely ionising particles with 
high biological effectiveness. As binary treatment, BNCT allows 
to optimise the treatment by manipulation of two independent 
parameters. One parameter is the boron concentration in tumour 
and healthy tissues in its vicinity. The other parameter is the 
thermal neutron fluence rate in the tumour and in the surrounding 
tissue. Damage to tumour tissue and to healthy tissue will be 
influenced by both of these parameters. 
In 1995 I was asked to participate in the first clinical trial on 
BNCT in Europe. I took part in the preparation and performance 
of this trans-national, multi-disciplinary  study from 1995 till 
2001 as study radiotherapist, responsible physician at the 
irradiation facility and task leader of the study centre Essen. I 
have played a major role in defining the trial design, writing the 
study protocol, creating the study structure, defining the standard 
operating procedures furthermore in conducting the study and 
evaluating the results. 
The EORTC BNCT Group conducts the first phase I study on 
BNCT. It is a radiation dose escalation trial on GBM patients with 
a constant blood boron level in order to study the feasibility of 
Na2B12H11SH (BSH) as boron carrier and to define maximal 
tolerated dose (MTD) and dose limiting toxicity (DLT) of BNCT 
in cranial localisation. The tissue uptake and pharmacokinetics of 
BSH have been studied in the first patient group. The trial is 
currently in progress at the European High Flux Reactor in Petten 
(NL). The study is performed according to the “Boron Neutron 
Capture Therapy with Glioblastoma Patients at the Petten 
Irradiation Facility” EORTC 11 961 phase I clinical “ protocol.  
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Purposes of the PhD study 
It is demonstrated in the present work what kind of challenges and 
difficulties should have been overcome in order to investigate 
whether BNCT a new, complex radiotherapy modality, using 
epithermal neutrons and BSH as boron compound can be applied 
in a safe manner for patients in a trans-European set-up. 
 
I. The preparation of the first clinical study in Europe will be 
presented. In addition to the difficulties defining a phase I trial 
design in the lack of established rules in the radiation oncology, 
the special features of BNCT had to be taken into consideration as 
well.  
 
I/1. Clear definition on the aim of the clinical trial, strategy, end 
points and evaluation criteria were established as a part of my 
work. 
  
I/2. I provide an inter-comparison on the currently ongoing 
clinical studies on BNCT. The achieved solutions, furthermore the 
general conclusions, which could be drawn for clinical research 
on highly selective new radiation therapy modalities are described 
in the present thesis. 
 
I/3. As a part of the clinical trial on BNCT BSH pharmacokinetics 
and tissue uptake investigation has been performed. In this PhD 
work, the results of the borocaptate uptake in glioblastoma 
multiforme and surrounding healthy tissues, its potential 
contribution on localisation of the energy deposition due to boron 
neutron capture reactions and its radiotherapeutical relevance is 
described.  
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I/4. In this work the particular dose concept is analysed which was 
defined specially for BNCT using epithermal neutron source in 
order to establish reproducible and comparable dose specification 
and reporting system as close to the standard recommendations in 
radiotherapy as it was possible. The limitations and achievements 
in the complex dose(s) handling are pointed out. 
 
II. Interim results in term of dose-effect relationship of the ongoing 
EORTC 11 961 phase I study is presented. 
 
III. The conclusion of the interim analysis of the ongoing trial and 
the direction of further investigations and future perspectives of 
BNCT are highlighted. 
 
 
 
New scientific results, conclusions and suggestions 
 
The approach on the trial design, patient selection, definition on 
end point, dose escalation strategy and toxicity detection 
corresponds to criterion of careful introduction of a complex 
radiation modality into the clinic. 
 
Establishment of a medical infrastructure and appropriate working 
conditions for an outpatient clinic at the nuclear reactor site 
applying the European standards and the accepted international 
rules of radiotherapy provides the basis of the safe patient 
treatment.  
 
The feasibility of performing BNCT using the epithermal beam at 
High Flux Reactor (HFR) Petten in a multinational approach 
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could be demonstrated. However the therapeutic potential of 
BNCT cannot yet be evaluated at this point. Glioblastoma 
multiforme constitutes a model for a phase I trial giving the 
opportunity to offer patients with a very poor prognosis and 
without expected benefit from all currently available treatments a 
therapeutic modality which at least shortens the treatment time. 
Glioblastoma multiforme however may not be the disease to judge 
the utility of BNCT and the therapeutic benefit deriving from 
BNCT. Future attempts will, therefore, focus on other tumour 
entities in addition to refining the protocol for glioblastoma 
patients. 
 
The quality management system proved to be essential to assure 
the high quality of the study, correct interpretation of the collected 
data and of patient treatment performance. 
 
After careful evaluation of the data, we can conclude that the 
starting BNCT dose level was safe but probably not high enough 
to reach the dose limiting toxicity within the frame of this 
radiation dose escalating trial. Early and late radiation toxicities 
are clearly lower compared to conventional radiotherapy for 
glioblastoma with photons at a dose of 60 Gy in 6 weeks. The 
results concerning survival are similar, as expected. 
 
The feasibility of using BSH for BNCT has been proved. Further 
reliable data should be collected on boron bio-distribution on 
macroscopic and sub-cellular scale. As well as the cellular uptake 
mechanism and the influence of the macro- and micro-
environment on it, should be investigated. However, on the basis 
of the present knowledge, further optimisation on boron delivery 
can be introduced in clinical research. As a next step, the 
maximal tolerated dose of BSH and the combined administration 
of BSH-BPA could be established in humans.  
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At the same time the optimisation of thermal neutron delivery 
can improve the results of the empirical clinical investigation on 
BNCT. In order to increase the accuracy of neutron transport 
calculation the tissue inhomogeneity should be taken into 
account. On that basis the boron dose should be calculated with 
realistic values of boron concentration of at least macroscopic 
volumes. To that aim in vivo boron imaging with acceptable 
resolution should be developed.  
The phase I study was an important step toward the development 
of early trial methodology for radiation oncology and served 
paramount information on BNCT which defines the direction of 
further investigations on neutron capture therapies.  
 
